References
- AstinMStjernschantzJSelénG1994Role of nitric oxide in PGF2 alpha-induced ocular hyperemiaExp Eye Res5940177532135
- BaudouinCRianchoLMWarnetJM2007In vitro studies of anti-glaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprostInvest Ophthalmol Vis Sci484123817724196
- BookSA1978Essentials of statisticsNew YorkMcGraw-Hill11722
- EpsteinSPChenDAsbellPAThe effect of travoprost Z, latanoprost and their individual components on the ocular surface (corneal and conjunctival epithelium)Presented at the Association for Research in Vision and Ophthalmology (ARVO)May 7, 2008Fort Lauderdale, FL
- FechtnerRBudenzDGodfreyD2008Prevalence of ocular surface disease symptoms in glaucoma patients on IOP-lowering medicationsPoster presented at: Annual meeting of the American Glaucoma SocietyMarch 8, 2008Washington DC
- GrossRLPeaceJHSmithSE2008Duration of IOP reduction with travoprost BAK-free solutionJ Glaucoma172172218414108
- JaenenNBaudouinCPouliquenP2007Ocular symptoms and signs with preserved and preservative-free glaucoma medicationsEur J Ophthalmol17341917534814
- KahookMYNoeckerRJ2008Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sof Zia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tearsCornea273394318362664
- KuppensEVde JongCAStolwijkTR1995Effect of timolol with and without preservative on the basal tear turnover in glaucomaBr J Ophthalmol79339427742279
- LewisRAKatzGJWeissMJ2007Travoprost BAC-free Study Group. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacyJ Glaucoma169810317224758
- ManniGCentofantiMOddoneF2005Interleukin-1beta tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockersAm J Ophthalmol13972715652830
- McCareyBEdelhauserH2007In vivo corneal epithelial permeability following treatment with prostaglandin analogs with or without benzalkonium chlorideJ Ocul Pharmacol Ther234455117941807
- MillerKLMinkDRMathiasSD2006Estimating the minimal clinical important difference of the Ocular Surface Disease Index®: preliminary findings [abstract] Abstract obtained from www.isoqol.org/2006AbstractsBook.pdf
- NoeckerRJHerrygersLAAnwaruddinR2004Corneal and conjunctival changes caused by commonly used glaucoma medicationsCornea23490615220734
- OzcuraFAydinSHelvaciMR2007Ocular surface disease index for the diagnosis of dry eye syndromeOcul Immunol Inflamm153899317972223
- PisellaPJPouliquenPBaudouinC2002Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBr J Ophthalmol864182311914211
- ScheinODMunozBTielschJM1997Prevalence of dry eye among the elderlyAm J Ophthalmol12472389402817
- SchiffmanRMChristiansonMDJacobsenG2000Reliability and validity of the Ocular Surface Disease IndexArch Ophthalmol1186152110815152
- WhitsonJTCavanaghHDLakshmanN2006Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chlorideAdv Ther236637117142200
- YeeRWNorcomEGZhaoXC2006Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture systemAdv Ther23511917050493
- YeeRW2007The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a reviewCurr Opin Ophthalmol18134917301615